Main Uses and Benefits of Hexalen (Altretamine)

Hexalen is an antineoplastic agent used in therapeutic protocols primarily for specific goals within cancer management.

Altretamine is used to help manage cancer of the ovaries that has not improved or has worsened after prior therapy with other medications. It is commonly used within therapeutic protocols to assist with disease control in specific clinical contexts.

---

Therapeutic Focus and Symptom Management

Hexalen is indicated for use in women with advanced, persistent, or recurrent ovarian carcinoma. This application is relevant for conditions associated with heightened physiological activity that requires supportive symptom management. The agent is considered relevant as a secondary or salvage treatment for adult patients who have relapsed following prior combination chemotherapy. It is applied in clinical settings that involve recurrent or episodic manifestations following prior treatments.

The therapeutic benefit supports the management of disease progression, helping patients cope more steadily with symptom fluctuations. This use supports the overall symptom burden associated with conditions where symptoms may intensify temporarily.

“The therapy assists with maintaining functional stability when symptoms become more noticeable, contributing to improved comfort during symptomatic periods.”

---

Quick Fact: Support in Advanced Disease
Primary Use	Applied across domains where additional symptomatic support is needed.
Therapeutic Context	Used as secondary or salvage monotherapy following prior treatments.
Patient Benefit	Contributes to easing the overall symptom load and supports general well-being.
Target Conditions	Conditions associated with acute or disruptive episodes that require supportive management.

Regulatory References

1. U.S. National Library of Medicine (NIH) MedlinePlus

The eligibility for Altretamine (Hexalen) is strictly governed by a patient’s pre-existing health status and is indicated solely for adult patients with persistent or recurrent ovarian cancer following prior therapy.

The medicine is absolutely contraindicated for patients who have shown hypersensitivity to Altretamine, or those with pre-existing severe bone marrow depression or severe neurologic toxicity, as stated in the official regulatory label.

Age-related eligibility rules dictate that the safety and effectiveness of the medicine have not been established in the pediatric population, effectively limiting its use to adults. Use is not recommended during pregnancy (due to FDA Category D classification, indicating potential fetal harm) and requires discontinuation of breastfeeding.

Specific condition-based restrictions govern the continuation of therapy. Treatment must be temporarily held if hematologic levels, such as the White Blood Count or platelet count, fall below established regulatory thresholds. Caution is also required for patients with hepatic or renal impairment or pre-existing neuropathies, as these conditions necessitate careful patient monitoring during treatment.

Hexalen Interactions with other medicines and products

Hexalen (Altretamine) has officially documented interaction patterns primarily involving metabolic pathways and pharmacodynamic additive effects, as outlined in regulatory prescribing information.

Pharmacokinetic and Metabolic Interactions

• Cimetidine: This medicine, documented as an inhibitor of microsomal drug metabolism, has been shown to increase Altretamine's half-life and potential toxicity.
• CYP450 Enzyme Stimulants: Co-administration of medicines that stimulate CYP450 enzymes, such as Barbiturates, may increase Altretamine's metabolic clearance. This increased clearance could potentially result in decreased therapeutic effects.

---

Pharmacodynamic and Other Restrictions

• Monoamine Oxidase (MAO) Inhibitors: Concurrent use of MAO inhibitors may cause severe orthostatic hypotension. This effect has been specifically reported in elderly patients over 60 years of age.
• Live Vaccines: Due to the drug's immunosuppressive properties, co-administration with Live Vaccines is advised against because it may diminish the immune response or increase the risk of infection.
• Supplements and Additive Effects: The regulatory data advises against the co-administration of the supplement Pyridoxine (Vitamin B6) because it is documented to adversely affect the duration of the therapeutic response. Furthermore, concurrent use with other myelosuppressive agents or anticoagulants/NSAIDs may lead to an additive risk of bone marrow suppression or bleeding complications.

---

This interaction profile is defined by regulatory agencies based on combinations that either significantly modify the drug’s systemic exposure via metabolic pathways or cause serious additive pharmacodynamic effects such as severe hypotension and increased toxicity risk. All stated constraints reflect the official requirements detailed in the drug's approved labeling.

Hexalen's mechanism initiates with metabolic activation, where it functions as a pro-drug requiring the CYP450 system to generate highly reactive intermediates like iminium species. These active molecules target cellular DNA and RNA, forming covalent adducts that cause strand breaks and cross-linking. This chemical damage modifies the core processes of replication and transcription, resulting in the inhibition of cell division.

Beyond genetic damage, the mechanism involves a critical functional distinction: the metabolites act as an inhibitor of Glutathione Peroxidase 4 (GPX4). By compromising this enzyme involved in oxidative defense, the drug alters the cell's oxidative stress regulation and initiates a specific, regulated form of cell death known as ferroptosis. This dual mechanistic action—molecular damage to genetic material combined with the induction of cell death—is the underlying physiological consequence, resulting in cytotoxicity in rapidly proliferating cells.

Hexalen (altretamine) is an antineoplastic agent that is administered according to a defined, intermittent schedule. The only officially approved route of administration for this medicine is oral, as it is supplied exclusively in a capsule form. The entire course of therapy is required to be under the supervision of a physician experienced in antineoplastic treatments.

Official Dosing and Frequency Patterns

The standard adult dosing regimen is precisely calculated based on the patient’s Body Surface Area (BSA), generally starting at 260 mg/m^2 per day. This total daily dose is not taken all at once but is divided into four separate oral administrations throughout the day.

This administration adheres to a cyclic treatment schedule. The drug is typically administered for a period of 14 or 21 consecutive days, followed by a scheduled rest period, to complete one full 28-day treatment cycle. Should intolerance occur, the official label details a process for dose modification, involving a temporary discontinuation followed by restarting at a reduced daily dose of 200 mg/m^2.

Administration Conditions and Protocols

Administration involves specific timing: the four divided doses should be taken after meals and at bedtime. This instruction is a necessary part of the defined procedure for proper use. If a dose is missed, standard protocols advise taking it as soon as it is remembered, but skipping it if it is almost time for the next scheduled dose, thereby avoiding a double dose. The labeling does not specify baseline dose adjustments for patients based solely on age or existing renal or hepatic function in the primary regimen.

Research Evidence / Overview of Studies for Hexalen (Altretamine)

Evidence for Use in Persistent or Recurrent Ovarian Carcinoma

Research for Altretamine was studied for women facing conditions involving periods of heightened symptoms of persistent or recurrent ovarian carcinoma following prior therapy. The initial research was conducted through Phase II clinical trials, which are generally smaller, non-comparative studies. These studies included populations of adult women with advanced disease who had already received and progressed on other chemotherapy regimens, such as those including platinum-based medicines.

These trials contribute to the broader evidence landscape by describing patterns of tumor change observed during the study periods. Initial research also explored the use of Altretamine by comparing it to other existing chemotherapy regimens in older, randomized study settings. Findings describe patterns observed in the studies where researchers monitored whether there was an objective change in the size of the tumor (known as objective response) in a portion of the previously treated patient population. This research contributed to the overall data landscape for the medicine's clinical evaluation in the setting of recurrence.

---

Types of Outcomes Measured in Clinical Trials

Research examined several different types of outcomes reflecting daily functioning or activity level and measures of disease course. The main outcomes studied included objective tumor assessment (measuring changes in tumor size), time without disease progression, and time periods related to survival.

Additionally, some trials gathered data on patient-reported outcomes describing perceived discomfort and outcomes monitoring physiological strain or stress. These measurements allowed researchers to report how symptoms evolved in the observed populations during the defined time intervals of the trials. These findings help contextualize how patients reported their experience of the condition while receiving Altretamine.

---

What Remains Uncertain About Altretamine Research

The existing body of research highlights what is known — and what is still uncertain. A primary limitation is the design of the research: much of the evidence comes from earlier Phase II studies, meaning that comparative evidence is lacking when trying to assess Altretamine directly against newer or standard treatments using modern, large-scale randomized trials.

Evidence quality varies across studies, and findings were observed in some studies that described varied outcomes across different patient characteristics. Overall, certainty remains low concerning definitive comparisons or absolute, long-term outcomes. The available research describes patterns observed in groups studied but does not determine whether an individual will respond similarly.

Key Studies & References

1. Altretamine: MedlinePlus Drug Information (National Library of Medicine - NIH)
2. WHO Model List of Essential Medicines (Relevant section for Antineoplastic Agents)

Common questions about Hexalen (FAQ)

---

Q: What are the specific risks associated with having low white blood cell counts while on Hexalen?

Official product information indicates that Hexalen can cause a significant decrease in blood cell counts, which is known as myelosuppression. When white blood cell counts, specifically, are low, the body's ability to fight off infections is reduced, potentially impairing the body’s ability to fight infection. The official label states that regular blood monitoring is necessary for monitoring before each course of therapy.

---

Q: Is severe nausea and vomiting from Hexalen considered normal, and is it manageable?

Nausea and vomiting are very common side effects associated with this medication. However, regulatory information states that in most cases, these symptoms can be controlled with anti-emetic medicines prescribed by a healthcare provider. Official guidance permits dose adjustment, such as a temporary discontinuation or reduction, when severe symptoms occur.

---

Q: Does Hexalen cause hair loss in most patients?

According to official adverse event summaries, alopecia, or hair loss, has been reported as an adverse effect of Hexalen. However, evidence suggests that the incidence of hair loss is relatively low, occurring in a small percentage of patients. It is not generally considered a side effect that affects most patients.

---

Q: Does Hexalen affect the heart or liver function?

Official product labeling indicates that taking this medicine may cause elevations in serum liver enzymes, which is a sign of liver stress or hepatotoxicity. Conversely, significant effects on heart function or major cardiotoxicity are not widely reported in the primary regulatory warnings for Hexalen.

---

Q: Is Hexalen considered safe for use in older adults?

Regulatory sources confirm that Hexalen is intended for use in the adult population. While official documents note a specific interaction risk for older adults taking certain other medicines (MAO inhibitors), the drug is not generally expected to cause different or more severe side effects in the older population than in younger adults.

---

Q: Are there any research findings regarding Vitamin B6 (pyridoxine) and Hexalen's neurotoxicity?

Studies and official information indicate that taking the supplement Pyridoxine (Vitamin B6) alongside Hexalen may reduce the occurrence of nerve problems (neurotoxicity). However, official data also documented that Pyridoxine negatively affected the therapeutic response, meaning it may reduce the medicine’s effectiveness against the cancer. For this reason, co-administration of Vitamin B6 is not recommended in official labeling.

---

Q: What does the term 'palliative treatment' mean when Hexalen is prescribed?

According to its regulatory classification, Hexalen is used for palliative treatment. This means the main purpose of the medicine is to help relieve symptoms caused by the cancer and manage the condition. It is not approved based on evidence that it can cure the disease.

---

Q: Does Hexalen cure cancer or is its purpose to manage symptoms?

Hexalen is indicated for the palliative treatment of recurrent ovarian cancer. Official sources state that the drug is used to manage symptoms and control cell proliferation but has not been shown to result in a cure for the disease.

---

Q: Is Hexalen still available for prescription in the United States?

No. Regulatory filings indicate that the brand-name medicine Hexalen (altretamine) has been officially discontinued in the United States and is no longer available for prescription. This information is based on manufacturer reports to the FDA.

---

Q: If Hexalen was discontinued, why is it still being discussed for treatment?

While the medicine has been discontinued, it is still discussed because it was previously a treatment option for recurrent ovarian cancer. Information about its use, side effects, and interaction profile remains important for informing patients and healthcare providers about alternative therapeutic approaches.

---

Q: Are the neurological side effects from Hexalen permanent?

Official documents state that neurotoxicity, which includes nerve symptoms like peripheral neuropathy, is often related to the dosage. Importantly, this side effect has been reported to be reversible once the medicine is stopped, either temporarily or permanently.

---

Q: Is it safe for a pregnant person to handle Hexalen capsules?

Due to its classification as a cytotoxic drug, specific caution is required. Regulatory-aligned patient education materials advise that pregnant or nursing women should avoid preparing the dose for a patient or handling the capsules. Specific procedures for handling and disposing of all cytotoxic drugs are required by regulation.

---

Q: Does Hexalen treatment affect fertility for men or women?

Official documents contain warnings related to reproductive health. The medicine has been noted to cause developmental toxicity and male reproductive toxicity. Women of childbearing potential are advised to use effective contraception due to the risk of harm to an unborn baby.

---

Q: Does Hexalen treatment increase the risk of getting infections like shingles (herpes zoster)?

Yes. Due to the drug's effect of suppressing the bone marrow, it can increase the risk of infection. Official safety information also specifically notes that patients with a history of varicella zoster or other herpes virus infections are at risk for reactivation (such as shingles) during treatment.

Hexalen (altretamine) capsules must be stored according to official regulatory requirements to maintain product stability and ensure safety. The medicine must be kept at room temperature in the container it came in, secured with a tightly closed lid.

Mandatory Storage Conditions

Condition	Requirement
Temperature	Store at room temperature (typically 20°C to 25°C).
Protection	Keep from freezing and protect from excessive heat, moisture, and direct light.
Child Safety	Must be kept out of the reach of children.

Official Disposal Instructions

Unused or expired capsules should not be kept in the home. Disposal should preferentially use an established drug take-back program. If one is unavailable, the capsules (which must not be crushed) should be mixed with an unappealing substance, sealed in a plastic bag, and placed in household trash, following published guidelines for safe disposal of anticancer drugs.